Subjects with lower postmenstrual ages required significantly higher enoxaparin doses to achieve therapeutic anti-factor Xa concentrations. Postmenstrual age may provide a more appropriate basis for dosing enoxaparin compared with gestational age and postnatal age.
Perez et al. (Wed,) studied this question.